Armata Pharmaceuticals Shares Outstanding History (ARMP)
Armata Pharmaceuticals reported 36.4M shares outstanding at the end of fiscal 2025.
View full Armata Pharmaceuticals company overviewArmata Pharmaceuticals annual shares outstanding history
| Fiscal year | Period ended | Shares outstanding | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 36.4M | 248,377 | +0.69% |
| 2024 | 2024-12-31 | 36.2M | 60,135 | +0.17% |
| 2023 | 2023-12-31 | 36.1M | −21,774 | −0.06% |
| 2022 | 2022-12-31 | 36.1M | 9.0M | +33.31% |
| 2021 | 2021-12-31 | 27.1M | 8.4M | +45.08% |
| 2020 | 2020-12-31 | 18.7M | 18.0M | +2537.81% |
| 2019 | 2019-12-31 | 708,484.921 | 682,640.135 | +2641.31% |
| 2018 | 2018-12-31 | 25,844.786 | 25,843.528 | +2053467.95% |
| 2017 | 2017-12-31 | 1.259 | 1.04 | +476.13% |
| 2016 | 2016-12-31 | 0.218 | −7.577 | −97.20% |
| 2015 | 2015-12-31 | 7.795 | 2.518 | +47.71% |
| 2014 | 2014-12-31 | 5.277 | −12,086.963 | −99.96% |
| 2013 | 2013-12-31 | 12,092.24 | — | — |
Armata Pharmaceuticals quarterly shares outstanding
| Fiscal quarter | Period ended | Shares outstanding | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 37.1M | 952,241 | +2.63% |
| Q4 2025 | 2025-12-31 | 36.4M | 248,377 | +0.69% |
| Q3 2025 | 2025-09-30 | 3.6M | −32.6M | −89.99% |
| Q2 2025 | 2025-06-30 | 36.2M | 37,487 | +0.10% |
| Q1 2025 | 2025-03-31 | 36.2M | 61,362 | +0.17% |
| Q4 2024 | 2024-12-31 | 36.2M | 60,135 | +0.17% |
| Q3 2024 | 2024-09-30 | 36.2M | 60,476 | +0.17% |
| Q2 2024 | 2024-06-30 | 36.2M | 28,686 | +0.08% |
| Q1 2024 | 2024-03-31 | 36.1M | −12,589 | −0.03% |
| Q4 2023 | 2023-12-31 | 36.1M | −21,774 | −0.06% |
| Q3 2023 | 2023-09-30 | 36.1M | −22,115 | −0.06% |
| Q2 2023 | 2023-06-30 | 36.1M | −888 | −0.00% |
| Q1 2023 | 2023-03-31 | 36.1M | 32,653 | +0.09% |
| Q4 2022 | 2022-12-31 | 36.1M | 9.0M | +33.31% |
| Q3 2022 | 2022-09-30 | 36.1M | 34.4M | +1927.75% |
| Q2 2022 | 2022-06-30 | 36.1M | 34.3M | +1929.03% |
| Q1 2022 | 2022-03-31 | 36.1M | 34.3M | +1927.92% |
| Q4 2021 | 2021-12-31 | 27.1M | 25.8M | +1931.86% |
| Q3 2021 | 2021-09-30 | 1.8M | 1.7M | +1772.91% |
| Q2 2021 | 2021-06-30 | 1.8M | 1.7M | +1773.61% |
| Q1 2021 | 2021-03-31 | 1.8M | 1.7M | +1773.49% |
| Q4 2020 | 2020-12-31 | 1.3M | 1.3M | +2537.81% |
| Q3 2020 | 2020-09-30 | 95,173.219 | 91,557.19 | +2531.98% |
| Q2 2020 | 2020-06-30 | 95,033.626 | 94,774.812 | +36618.80% |
| Q1 2020 | 2020-03-31 | 95,049.899 | 95,045.557 | +2188789.29% |
| Q4 2019 | 2019-12-31 | 50,585.823 | 50,581.545 | +1182172.54% |
| Q3 2019 | 2019-09-30 | 3,616.029 | 3,613.847 | +165627.13% |
| Q2 2019 | 2019-06-30 | 258.815 | 256.633 | +11761.80% |
| Q1 2019 | 2019-03-31 | 4.342 | 2.161 | +99.06% |
| Q4 2018 | 2018-12-31 | 4.279 | 3.02 | +239.98% |
| Q3 2018 | 2018-09-30 | 2.182 | 0.946 | +76.59% |
| Q2 2018 | 2018-06-30 | 2.182 | 1.049 | +92.63% |
| Q1 2018 | 2018-03-31 | 2.181 | −0.003 | −0.14% |
| Q4 2017 | 2017-12-31 | 1.259 | −0.926 | −42.39% |
| Q3 2017 | 2017-09-30 | 1.236 | −13.498 | −91.61% |
| Q2 2017 | 2017-06-30 | 1.133 | −13.601 | −92.31% |
| Q1 2017 | 2017-03-31 | 2.184 | −5.611 | −71.98% |
| Q4 2016 | 2016-12-31 | 2.184 | −5.611 | −71.98% |
| Q3 2016 | 2016-09-30 | 14.734 | 6.938 | +89.01% |
| Q2 2016 | 2016-06-30 | 14.734 | −18,398.125 | −99.92% |
| Q1 2016 | 2016-03-31 | 7.795 | −13,185.686 | −99.94% |
| Q4 2015 | 2015-12-31 | 7.795 | −12,390.735 | −99.94% |
| Q3 2015 | 2015-09-30 | 7.795 | −12,390.735 | −99.94% |
| Q1 2015 | 2015-03-31 | 18,412.859 | 6,320.619 | +52.27% |
| Q4 2014 | 2014-12-31 | 13,193.482 | 1,101.241 | +9.11% |
| Q3 2014 | 2014-09-30 | 12,398.53 | — | — |
| Q2 2014 | 2014-06-30 | 12,398.53 | — | — |
| Q1 2014 | 2014-03-31 | 12,092.24 | — | — |
| Q4 2013 | 2013-12-31 | 12,092.24 | — | — |
Armata Pharmaceuticals shares outstanding trends
Over the last five reported fiscal years, Armata Pharmaceuticals's shares outstanding moved from 18.7M to 36.4M, a change of 17.7M. The latest reported quarter, Q2 2026, shows 37.1M.
What shares outstanding means
Shares outstanding is the number of common shares held by investors at a reporting-period end. The count can change because of stock issuance, repurchases, conversions, acquisitions, or stock splits.
SEC-reported period-end shares
TickerStat displays period-end common shares from SEC filings and adjusts older values to the current share basis when SEC-reported stock-split conversion ratios are available. Values remain as reported when no split ratio is available. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Armata Pharmaceuticals filings at SEC.gov ↗